Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 30Carcinoma, Non-Small-Cell Lung 30Lung Neoplasms 23Head and Neck Neoplasms 21Squamous Cell Carcinoma of Head and Neck 15Lymphoma 15Gliosarcoma 15Central Nervous System Neoplasms 14Sarcoma 12Esophageal Neoplasms 12Rectal Neoplasms 10Glioma 10Leukemia 9Breast Neoplasms 9Brain Neoplasms 9Prostatic Neoplasms 8Pancreatic Neoplasms 8Lymphoma, Follicular 7Esophageal Squamous Cell Carcinoma 7Neoplasms 6Melanoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Uterine Cervical Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Astrocytoma 5

Interventions

Radiotherapy 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Non-Metastatic Prostate Cancer × Radiotherapy × Clear all
NCT00239291 2009-04-23

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

AstraZeneca

Phase 1/2 Completed
42 enrolled
Genitourinary

Non-Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡